Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

1.(currently amended) A compound having the formula

$$(R^{1})_{m} \xrightarrow{R^{2}} R^{9} \xrightarrow{H} N - R^{5}$$

$$(CH_{2})_{n} \xrightarrow{O}$$

wherein:

R¹ is H, NO₂, halo, NR⁶R⁷, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkyl, R⁶CO₋₆alkyl, R⁶CO, R⁶OCO or CONR⁶R⁷:

m is 0, 1, 2 or 3;

R² is NO₂, halo, NR⁶R⁷, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, cyano, R⁶OC₀₋₆alkyl, R⁶CO, R⁶OCO, R⁶CONR⁷, R⁶R⁷NCO, R⁸SO₂, R⁸SO₂HN, arylC₀₋₆alkyl or heteroarylC₀₋₆alkyl:

R3 and R9 are each independently H or C1-4alkyl;

p is 0, 1 or 2;

n is 0, 2, 3 or 4;

R⁵ is C₁₋₁₀alkyl, C₆₋₁₀arylC₀₋₆alkyl, C₃₋₇cycloalkylC₀₋₆alkyl or C₅₋₆heteroarylC₀₋₆alkyl, whereby any aryl, heteroaryl or cycloalkyl may be fused with aryl, heteroaryl.

 $C_{3\text{--}7}$ cycloalkyl or $C_{3\text{--}7}$ heterocycloalkyl, and which R^5 may be substituted with one or more A;

A is H, OH, NO2, cyano, R6CO, R6O(CO), halo, C1-6alkyl, NR6R7, C1-6haloalkyl,

 $C_{1\text{-}6} haloalkylO,\, R^6 O C_{0\text{-}6} alkyl,\, hydroxyC_{1\text{-}6} alkyl,\, R^8 S O_2,\, R^8 S O_2 H N,\, C_{5\text{-}6} arylO \,\, or \,\, CONR^6 R^7;$

R⁶ and R⁷ are each independently H or C₁₋₆alkyl; and

R8 is NR6R7 or C1-4alkyl.

or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the provise that the compound is not methyl 4 [[(7 methyl III benzimidazol 1 yl)acetyllamino]benzoate.

US Application No. 10/556,229
Amendment dated 1/21/2009
AstraZeneca Docket Number 101062-1P US

(currently amended) A compound according to claim 1, wherein:

 $R^{l} \text{ is H, halo, } NR^{6}R^{7}, C_{l\cdot6}\text{alkyl, } C_{l\cdot6}\text{haloalkyl, } C_{l\cdot6}\text{haloalkylO, } R^{6}OC_{0\cdot6}\text{alkyl, } R^{6}CO, \\ R^{6}OCO \text{ or } CONR^{6}R^{7}\text{:}$

m is 0 or 1:

 R^2 is NO₂, halo, NR⁶R⁷, C₁₋₆alkyl, C₁₋₆haloalkyl, cyano, R⁶OCO, R⁶CONR⁷, R⁸SO₂, R⁸SO₂HN or heteroarylC₀₋₆alkyl:

R3 and R9 are each independently H or C1.4alkyl:

p is 0;

n is 0;

 R^5 is $C_{1:10}$ alkyl, $C_{6:10}$ aryl $C_{0:6}$ alkyl or $C_{5:6}$ heteroaryl $C_{0:6}$ alkyl, whereby any aryl may be fused with $C_{2:7}$ eycloalkyl or $C_{3:7}$ heterocycloalkyl, and which R^5 may be substituted with one or more A:

A is H, cyano, halo, NO₂, C₁₋₆alkyl, NR⁶R⁷, C₁₋₆haloalkyl, C₁₋₆haloalkylO, R⁶OC₀₋₆alkyl, hydroxyC₁₋₆alkyl, R⁸SO₂ or C₅₋₆arylO;

R6 and R7 are each independently H or C1.6alkyl; and

R8 is NR6R7 or CL4alkyl.

or a pharmaccutically acceptable salt thereof, solvate or solvated salt thereof, with the proviso that the compound is not methyl 4.ff(7-methyl-1H-benzimidazol-1-yl)acetyllaminolbenzeate.

3.(currently amended) A compound according to claim 1, wherein

R² is NO₂, halo, NR⁶R⁷, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₂haloalkylO, cyano, R⁶OC₀₋₄alkyl, R⁶CO, R⁶OCO, R⁶CONR⁷, R⁶R⁷NCO, R⁸SO₂, R⁸SO₂HN, arylC₀₋₆alkyl and heteroaryl and wherein

R6 and R7 are each independently H or C1-4alkyl and

R8 is NR6R7 or C1.3alkvl.

or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the provise that the compound is not methyl 4-[[(7-methyl-1H-benzimidazol-1-yl)acety|]amino]benzoate.

4.(currently amended) A compound according to claim 1, wherein R² is NO₂,

US Application No. 10/556,229 Amendment dated 1/21/2009 AstraZeneca Docket Number 101062-1P US

or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the provise that the compound is not methyl 4-ff(7-methyl-HH-benzimidazel-L-yl)acetyl|amino|benzoate,

5.(currently amended) A compound according to claim 1, wherein \mathbb{R}^5 is phenyl, which may be substituted with one or more \mathbb{A}_5

or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the provise that the compound is not methyl 4-ff(7-methyl-1H-benzimidazol-1-yl)acetyllaminolbenzoate,

6.(currently amended) A compound according to claim 5, wherein A is selected from the group consisting of halo, alkoxy, haloalkoxy, haloalkyl, alkyl, alkanol, cyano, phenoxy, alkylsulfonyl and (di)alkylamino.

or a pharmaccutically acceptable salt thereof, solvate or solvated salt thereof, with the proviso that the compound is not methyl 4 [[(7 methyl 1H benzimidazel 1 yl)acetyl]amino]benzoate.

7.(currently amended) A compound according to claim 1, wherein A is selected from the group consisting of fluoro, iodo, chloro, bromo, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, tetrafluoroethoxy, methyl, ethyl, propyl, butyl, hvdroxyethyl, evano, phenoxymethylsulfonyl and dimethylamino.

or a pharmaccutically acceptable salt thereof, solvate or solvated salt thereof, with the provise that the compound is not methyl 4 f[(7-methyl-1H benzimidazol-1-yl)acetyl]amino]benzoate.

8.(previously amended) A compound selected from the group consisting of:

N-(3-Fluoro-4-methoxy-phenyl)-2-(7-nitro-1H-benzimidazol-1-yl)-acetamide,

N-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(3-Chloro-4-iodophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(3-Chloro-4-methoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[3-(Difluoromethoxy)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(3,5-Difluorophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)phenyl]acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-vl)-*N*-[3-(1.1.2.2-tetrafluoroethoxy)phenyllacetamide.
- N-(4-tert-Butylphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-[3-(1-Hydroxyethyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)phenyl]acetamide,
- N-(3-Chlorophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-Hexyl-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(3,4-Difluorophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(4-Cvanophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-(2,3-Dihydro-1,4-benzodioxin-6-vl)-2-(7-nitro-1H-benzimidazol-1-vl)acetamide.
- N-(2-Bromobenzyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1H-benzimidazol-1-vl)-N-[3-(trifluoromethyl)benzyl]acetamide.
- N-(4-Methylpyridin-2-vl)-2-(7-nitro-1H-benzimidazol-1-vl)acetamide.
- N-(3-Cvanophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-(3.5-Dimethoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-(4-Methoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide.
- N-(3.4-Dimethoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- 2-(7-Nitro-1H-benzimidazol-1-vl)-N-(3.4.5-trimethoxyphenyl)acetamide.
- 2-(7-Nitro-1*H*-benzimidazol-1-v1)-*N*-[3-(trifluoromethoxy)phenyllacetamide.
- 2-(7-Nitro-1H-benzimidazol-1-vl)-N-(3-phenoxyphenyl)acetamide.
- N-(4-Butvlphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-(2-Fluoro-4-iodophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- 2-(7-Nitro-1H-benzimidazol-1-vl)-N-[2-(trifluoromethoxy)phenyllacetamide.
- N-(4-Methoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- 2-(7-Nitro-1H-benzimidazol-1-vl)-N-(2-phenoxyphenyl)acetamide.
- N-(4-Bromo-2-fluorophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-[3-(Methylsulfonyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-[4-(Methylsulfonyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- 2-(7-Nitro-1*H*-benzimidazol-1-vI)-*N*-[4-(trifluoromethyl)benzyl]acetamide.
- N-(4-tert-Butvlbenzyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.
- N-(2,3-dihydro-1H-inden-5-vl)-2-(7-nitro-1H-benzimidazol-1-vl)acetamide.
- 2-(7-Nitro-1H-benzimidazol-1-yl)-N-[4-(trifluoromethoxy)benzyl]acetamide,

```
N-(4-Isopropylphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
```

N-(3.4-Dimethylphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide.

N-1,3-Benzodioxol-5-yl-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-[3-Bromo-4-(trifluoromethoxy)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(3-Fluoro-2-methoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

N-(3,5-dimethoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)propanamide,

N-(3-Ethoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)propanamide,

2-(7-Nitro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]propanamide,

N-(3,5-Dimethylphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

2-(7-Nitro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,

2-(7-Bromo-1H-benzimidazol-1-vl)-N-(3.5-dimethoxyphenvl)acetamide,

2-(7-Bromo-1H-benzimidazol-1-v1)-N-(3-methoxyphenyl)acetamide,

2-(7-Bromo-1H-benzimidazol-1-vl)-N-[3-(trifluoromethyl)phenyllacetamide.

2-(7-Chloro-1H-benzimidazol-1-vl)-N-(3.5-dimethoxyphenyl)acetamide.

2-(7-Chloro-1H-benzimidazol-1-vl)-N-[3-(trifluoromethyl)phenyllacetamide.

2-(7-Chloro-1H-benzimidazol-1-v1)-N-(4-methylphenyl)acetamide.

2-(7-Chloro-1H-benzimidazol-1-yl)-N-(2,3-dihydro-1H-inden-5-yl)acetamide,

2-(7-Methyl-1H-benzimidazol-1-yl)-N-(4-methylphenyl)acetamide,

N-(3.5-Dimethoxyphenyl)-2-(7-methyl-1H-benzimidazol-1-yl)acetamide.

2-(7-Methyl-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyllacetamide.

N-(2.3-Dihydro-1H-inden-5-vl)-2-(7-methyl-1H-benzimidazol-1-vl)acetamide.

Methyl 1-{2-[(3,4-dimethylphenyl)amino]-2-oxoethyl}-1H-benzimidazole-7-carboxylate.

Methyl 1-[2-(2,3-dihydro-1*H*-inden-5-ylamino)-2-oxoethyl]-1*H*-benzimidazole-7-carboxylate.

Methyl 1-{2-[(4-tert-butylbenzyl)amino]-2-oxoethyl}-1H-benzimidazole-7-carboxylate.

Methyl 1-(2-{[3-methoxy-5-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-1*H*-benzimidazole-7-carboxylate.

Methyl 1-{2-[(3.5-dimethoxyphenyl)amino]-2-oxoethyl}-1H-benzimidazole-7-carboxylate.

N-(3,5-Dimethoxyphenyl)-2-{7-[(dimethylamino)sulfonyl]-1H-benzimidazol-1-yl}acetamide,

2-{7-[(Dimethylamino)sulfonyl]-1H-benzimidazol-1-vl}-N-[3-

(trifluoromethyl)phenyl]acetamide,

N-(3.5-Dimethoxyphenyl)-2-[7-(propylsulfonyl)-1H-benzimidazol-1-yl]acetamide.

2-[7-(Propylsulfonyl)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide.

US Application No. 10/556,229 Amendment dated 1/21/2009 AstraZeneca Docket Number 101062-1P US

- N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-[7-(methylsulfonyl)-1*H*-benzimidazol-1-yllacetamide,
- ${\it N-} (3,5-{\rm Dimethoxyphenyl})-2-[7-({\rm trifluoromethyl})-1{\it H-} {\rm benzimidazol-1-yl}] acetamide,$
- $N\hbox{-}(3,4\hbox{-Dimethylphenyl})\hbox{-}2\hbox{-}[7\hbox{-}(trifluoromethyl})\hbox{-}1H\hbox{-benzimidazol-1-yl}] ace tamide,$
- N-(4-tert-Butylbenzyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
- N-(2,3-Dihydro-1H-inden-5-yl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
- 2-(7-Cyano-1H-benzimidazol-1-yl)-N-(3,5-dimethoxyphenyl)acetamide,
- 2-(7-Cyano-1H-benzimidazol-1-yl)-N-(3-methoxyphenyl)acetamide,
- 2-(7-Cyano-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
- 2-(7-Cyano-1H-benzimidazol-1-yl)-N-(2,3-dihydro-1H-inden-5-yl)acetamide,
- N-(2.3-Dihydro-1H-inden-5-yl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide.
- N-(3,5-Dimethoxyphenyl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
- N-(4-tert-Butylbenzyl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Amino-1*H*-benzoimidazol-1-v1)-N-[3-(trifluoromethyl)phenyllacetamide.
- 2-[7-(Acetylamino)-1H-benzoimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
- 2-{7-[(Methylsulfonyl)amino]-1H-benzoimidazol-1-yl}-N-[3-

(trifluoromethyl)phenyllacetamide.

- 2-[7-(Dimethylamino)-1H-benzoimidazol-1-vll-N-[3-(trifluoromethyl)phenyllacetamide.
- 2-[7-(Isopropylamino)-1H-benzoimidazol-1-vl]-N-[3-(trifluoromethyl)phenyllacetamide.
- $\label{eq:n-constraint} N-(3,5-Dimethoxyphenyl)-2-[7-(1H-tetrazol-5-yl)-1H-benzimidazol-1-yl] acetamide, and$
- 2-(6,7-Difluoro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
- or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof.

9.(previously amended) A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to claim 1, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.